Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Innate Pharma, Lowers Price Target to $9

SVB Leerink analyst Daina Graybosch maintains Innate Pharma (NASDAQ:IPHA) with a Outperform and lowers the price target from $10 to $9.
byBenzinga Newsdesk
November 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Daina Graybosch maintains Innate Pharma (NASDAQ:IPHA) with a Outperform and lowers the price target from $10 to $9.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts